Phase 2 N=168 BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) — 2.63; 4.11; 4.17 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.
Alzheimer's Disease
Primary: Cognitive Performance — 15.92; 16.67; 8.58; 8.41 mean total correct responses — p=<0.05
Phase 2 N=126 A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.
Human Influenza
Primary: Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm^2, Against Each of Three Vaccine Strains After Receiving One Dose of TIV. — 62; 52; 51; 40…
Phase 2 N=29 Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression Free Survival (PFS) Rate at 6 Months — 55.2 percentage of patients
Phase 2 N=10 Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Basal Cell Carcinoma · Gorlin Syndrome · Nevoid Basal Cell Carcinoma Syndrome
Primary: Clinical Clearance Assessment of Main Target Basal Cell Carcinomas (BCCs) — 3; 0; 3; 0 Participants
Phase 2 N=244 Musculoskeletal Effects of Bicarbonate
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
Phase 2 N=46 Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Melanoma
Primary: Percentage of Participants Who Received Ipilimumab and Who Had Grade 3-4 Drug-related Skin Adverse Events (AEs) — 32.6 Percentage of participants
Phase 2 N=6 Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Adenocarcinoma of the Esophagus · Adenocarcinomas of the Gastroesophageal Junction · Recurrent Esophageal Cancer
Primary: Overall Response — 2; 4 patients
Phase 2 N=39 Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
Schizophrenia
Primary: Response Rates in the ECT Plus Clozapine Group vs the Pharmacotherapy Group. — 50; 0 Percentage of responders
Phase 2 N=69 Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
Dermatitis, Atopic
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4 — -81.7; -29.9 percent change — p=<0.0001
Phase 2 N=547 Safety Study of Apixaban in Recent Acute Coronary Syndrome
Acute Coronary Syndrome (ACS)
Primary: Event Rate of Composite of Adjudicated Major Bleeding and Clinically Relevant Non-Major Bleeding During the Treatment Period- Treated Participants With Placebo or…
Phase 2 N=153 A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
Pancreatic Cancer
Primary: Number of Participants Who Died During the Study — 102; 27 participants
Phase 2 N=498 Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
Heart Failure With Reduced Ejection Fraction
Primary: Number of Participants Experiencing Hypotension, Renal Dysfunction, Hyperkalemia and Angioedema and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low)…
Phase 2 N=210 Pioglitazone in Early Parkinson's Disease
Parkinson's Disease
Primary: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to 44 Weeks — 4.42; 5.13; 6.25 units on a scale
Phase 2 N=30 A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects
Chronic Hepatitis C
Primary: Change From Baseline at Day 7 in log10 Hepatitis C Virus (HCV) RNA of All Participants — -2.13; -3.31; -2.91; -2.58 log10 IU/mL